Vivera Pharmaceuticals Licenses TABMELT®, a Sublingual Pharmaceutical Drug-Delivery System for Cannabidiol (CBD)

    0
    254
    Reading Time: 3 minutes

    Company to focus on benefits of CBD for non-addictive pain management
    and opioid, alcohol addiction recovery

    NEWPORT BEACH, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CBD?src=hash” target=”_blank”gt;#CBDlt;/agt;–Vivera
    Pharmaceuticals, Inc.
    , a pharmaceutical company focused on
    non-addictive pain management, today announces the debut of TABMELT®, a
    sublingual drug delivery system that Vivera has exclusively licensed for
    the specific use for pharmaceutical cannabinoids, including cannabidiol
    (CBD), a non-psychoactive compound derived from hemp, and other
    hemp-derived and biosynthetic cannabinoid compounds.

    “According to the Centers for Disease Control and Prevention, on
    average, 130 Americans die every single day from an opioid overdose,”
    said Dr. Jon Norman, Chief Scientific Officer at Vivera. “We believe CBD
    has several important roles to play in this national crisis. It may
    offer a non-addictive way to manage pain and may create an alternative
    to starting patients on opioids in the first place. In addition, it may
    hold promise as a way to ease the detox process for patients in drug or
    alcohol recovery.”

    Internationally patented and U.S. patent-pending TABMELT® may optimize
    the pharmaceutical delivery of CBD by offering a sublingual, set-dose
    system, which may enhance bioavailability by largely avoiding first-pass
    metabolism through the liver.

    “Vivera’s commitment to innovative research, product development, and
    providing non-addictive therapies and treatments to patients is the
    foundation of our work,” said Olivia Karpinski, Co-founder and Executive
    Vice President of Vivera. “Our goal is to provide a non-addictive
    solution to patients nationwide who seek to manage pain and opioid
    cessation and deterrence in a safer way.”

    Vivera is headquartered in Newport Beach, California.

    For more information, visit https://viverapharma.com.

    About Vivera Pharmaceuticals, Inc.

    Vivera Pharmaceuticals, Inc. is an innovative, science-driven
    pharmaceutical company focused on opioid deterrence and cessation and
    non-addictive solutions for pain management.

    In addition to its pharmaceutical and medical device products, the
    company has global exclusivity to license the patented and
    patent-pending TABMELT® sublingual drug-delivery system for the
    pharmaceutical use of cannabinoid compounds.

    Vivera Pharmaceuticals is seeking to conduct case studies and clinical
    trials on CBD in the TABMELT® drug delivery format with the goal of
    gaining FDA approval for its products.

    The company is vertically integrated with patented technology,
    manufacturing capabilities and distribution for its products.

    For more information, visit https://viverapharma.com.

    Forward-looking and cautionary statements:

    The securities described herein, if any, have not been, and will not be,
    registered under the United States Securities Act of 1933, as amended
    (the “U.S. Securities Act”), or any state securities laws, and may not
    be offered or sold within the United States or to, or for the benefit
    of, U.S. persons (as defined in Regulation S under the U.S. Securities
    Act) except in compliance with the registration requirements of the U.S.
    Securities Act and applicable state securities laws or pursuant to
    exemptions therefrom. This release does not constitute an offer to sell
    or a solicitation of an offer to buy of any of Vivera Pharmaceuticals
    securities in the United States. This news release may contain
    “forward-looking information” as defined in applicable Canadian
    securities legislation. All statements other than statements of
    historical fact included in this release, including, without limitation,
    future operating margins, future production and processing, processing
    results, and future plans and objectives of Vivera Pharmaceuticals,
    constitute forward looking information that involve various risks and
    uncertainties. Forward-looking information is based on a number of
    factors and assumptions which have been used to develop such information
    but which may prove to be incorrect, including, but not limited to,
    assumptions in connection with the continuance of Vivera Pharmaceuticals
    and its subsidiaries as a going concern, general economic and market
    conditions, price of biomass, the accuracy of production resource
    estimates, and the performance of Vivera Pharmaceuticals future
    operations. There can be no assurance that such information will prove
    to be accurate and actual results and future events could differ
    materially from those anticipated in such forward-looking information.
    Important factors that could cause actual results to differ materially
    from Vivera Pharmaceuticals’ expectations include but are not limited
    to: changes in economic conditions or financial markets; increases in
    costs; litigation; legislative, environmental and other judicial,
    regulatory, political and competitive developments; and technological or
    operational difficulties. This list is not exhaustive of the factors
    that may affect our forward-looking information. These and other factors
    should be considered carefully, and readers should not place undue
    reliance on such forward-looking information. For additional information
    with respect to risk factors applicable to Vivera Pharmaceuticals,
    reference should be made to Vivera Pharmaceuticals continuous disclosure
    materials filed from time to time with securities regulators, including,
    but not limited to, Vivera Pharmaceuticals CSE Listing Statement. The
    forward-looking information contained in this release is made as of the
    date of this release. Vivera Pharmaceuticals does not intend, and
    expressly disclaims any intention or obligation to update or revise any
    forward-looking information whether as a result of new information,
    future events or otherwise, except as required by applicable law. The
    CSE has not reviewed, approved or disapproved the contents of this press
    release.

    Contacts

    Investor Relations and Canadian Media Enquiries:
    ThinkHERO
    Patrick
    Piette, CFA for Vivera Pharmaceuticals, Inc.
    416-526-9911
    [email protected]

    U.S. Media Inquiries:
    SRPR
    Brenda Patterson for Vivera
    Pharmaceuticals, Inc.
    949-667-1943
    [email protected]